Ecopipam Hydrochloride not checked
Emalex Biosciences Inc. · PSYRX101 · SCH 39166
FollowEvery change as it happens, and a Monday email
Trials
1 active
15 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Tourette Syndrome
- Main trialPhase 3
- “The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).”In the company’s words, NCT06021522 on ClinicalTrials.gov
- Other names
- Ecopipam · PSYRX101 · SCH 39166 · ecopipam HCL
Other drugs for Tourette Syndrome
- SCI-110Neurothera Labs Inc. · Phase 2
- GemlapodectNoema Pharma AG · Phase 2
Coming up1
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Feb 2028 | A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder | |
| Phase 3Terminated | Dec 2013 | Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease | |
| Phase 3Completed | 13 Jan 2025 | Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults | |
| Phase 2Completed | May 2012 | Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble | |
| Phase 2Completed | Dec 2019 | Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years | |
| Phase 2Completed | 23 Sep 2021 | Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents | |
| Phase 2Completed | 7 Mar 2022 | Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely) | |
| Phase 2Completed | 11 Nov 2022 | Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension | |
| Phase 1Terminated | 2 Apr 2021 | Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates | |
| Phase 1Completed | 6 Jul 2021 | Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite | |
| Phase 1Completed | 7 Sep 2021 | Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects | |
| Phase 1Completed | 1 Aug 2022 | Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport | |
| Phase 1Completed | 7 May 2023 | Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization | |
| Phase 1Completed | 14 May 2024 | Drug Interaction Study | |
| Phase 1Completed | 22 Dec 2024 | Food-effect Study of Ecopipam Pharmacokinetics |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026